BDNF serum levels and promoter methylation of BDNF exon I, IV and VI in depressed patients receiving electroconvulsive therapy

Kleimann A, Kotsiari A, Sperling W, Groeschl M, Heberlein A, Kahl KG, Hillemacher T, Bleich S, Kornhuber J, Frieling H (2015)

Publication Type: Journal article

Publication year: 2015

Journal

Journal of Neural Transmission Springer Nature

Book Volume: 122

Pages Range: 925-8

Journal Issue: 6

DOI: 10.1007/s00702-014-1336-6

Abstract

We examined potential changes in brain-derived neurotrophic factor (BDNF) serum levels and promoter methylation of the BDNF gene in 11 patients with treatment-resistant major depressive disorder during a series of electroconvulsive therapy (ECT). Blood samples were taken before, 1 and 24 h after ECT treatment sessions 1, 4, 7 and 10. Patients remitting under ECT had significantly lower mean promoter methylation rates, especially concerning the exon I promoter, compared to non-remitters (both p < 0.002). These findings may point to a depression subtype in which ECT is particularly beneficial.

Authors with CRIS profile

Johannes Kornhuber Lehrstuhl für Psychiatrie und Psychotherapie

Involved external institutions

Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) celerion CH Switzerland (CH)

How to cite

APA:

Kleimann, A., Kotsiari, A., Sperling, W., Groeschl, M., Heberlein, A., Kahl, K.G.,... Frieling, H. (2015). BDNF serum levels and promoter methylation of BDNF exon I, IV and VI in depressed patients receiving electroconvulsive therapy. Journal of Neural Transmission, 122(6), 925-8. https://doi.org/10.1007/s00702-014-1336-6

MLA:

Kleimann, Alexandra, et al. "BDNF serum levels and promoter methylation of BDNF exon I, IV and VI in depressed patients receiving electroconvulsive therapy." Journal of Neural Transmission 122.6 (2015): 925-8.

BibTeX: Download